Hellenic journal of nuclear medicine最新文献

{"title":"Radiopharmaceuticals used for diagnosis and therapy of NETs.","authors":"Maria Papachristou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The first description of the in vivo visualization of somatostatin receptor-positive tumors in patients was based on the use of a radioiodine (<sup>123</sup>I) labelled somatostatin analogue (Krenning et al. 1989). In the years that followed an Indium-111 (<sup>111</sup>In) labelled somatostatin analogue, chelated with diethylenetriaminepentaacetic acid (DTPA), was successfully developed. Subsequently, <sup>111</sup>In-OctreoScan was introduced worldwide. In the years to come <sup>99m</sup>Tc-Tektrotyde became commercially available with easy access. In the last decade, with the increasing use of positron emission tomography (PET) imaging, somatostatin analogues have been labelled with various positron-emitting isotopes, such as Gallium-68 (<sup>68</sup>Ga) and Copper-64 (<sup>64</sup>Cu) (Lewis et al. 1999, Schottelius et al. 2004, Gabriel et al. 2007) e.g <sup>68</sup>Ga-DOTATOC, <sup>68</sup>Ga-DOTATATE <sup>68</sup>Ga-DOTANOC and <sup>68</sup>Cu-DOTATATE. Scintigraphy with these investigational compounds display encouraging good imaging quality amd improved sensitivity in tumor site detection compared with SPECT scintigraphy. Also, other PET radiopharmaceuticals were developed, such as <sup>18</sup>F-dihydroxy-phenyl-alanine (<sup>18</sup>F-DOPA) and <sup>11</sup>C-labelled 5-hydroxytryptophan (<sup>11</sup>C-5-HTP) with encouraging results in terms of visualization of GEP-NETs (Koopmans et al. 2008). After the successful introduction of SRS in the diagnosis and staging of NETs, the next logical step was to increase the administered activity so that the radiopharmaceutical can induce tumor shrinkage in patients who had inoperable and/or metastasized NENs. Therefore, the first peptide receptor radionuclide therapy (PRRT) was performed with high administered activity of [<sup>111</sup>In-DTPA0] octreotide (Krenning et al. 1994a). To make significant advancements in the treatment of somatostatin receptor-positive metastatic disease, more efficient radiolabelled somatostatin analogues were developed with higher affinity to the somatostatin receptor. Treatment with radiolabelled peptides or PRRT is a promising new therapeutic option in the management of inoperable or metastasized NETs. Symptomatic control can be achieved with all <sup>111</sup>In-, <sup>90</sup>Y- and <sup>177</sup>Lu-labelled somatostatin analogue-based PRRT. For objective response and long-lasting duration of response, <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATATE are the most promising radiopharmaceuticals. Side effects of PRRT are few and mild, if adequate kidney protective measures are taken and dose-limits are respected. In a minority of patients, when SRS fails to identify neuroendocrine disease, MIBG scintigraphy and subsequent <sup>131</sup>I-MBG therapy might be an alternative treatment option. Targeted alpha-particle therapy (TAT) has emerged as an alternative treatment option to beta emitters in PRRT. The use of alpha emitters for cancer therapy has two ad","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"19-20"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of positron computed tomography (PET/CT) in lung cancer staging.","authors":"Emmanouil Panagiotidis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related mortalities with the rate of incidence reaching about 1.5 million cases per year worldwide. Approximately 350 people die each day from lung cancer in USA-nearly 2.5 times more than the number of people who die from colorectal cancer (CRC), which is the second leading cause of cancer death overall. In 2023, an estimated 238,340 people (117,550 men and 120,790 women) will be diagnosed with lung cancer, and 127,070 people will die from the disease. Although approximately 80% of lung cancers are caused by cigarette smoking, the toll among people who have never smoked is substantial, ranking among the top 10 causes of cancer death when categorized separately. Lung cancer encompasses a variety of biologically distinct tumours. The two primary types of lung cancer are non-small cell lung cancer (NSCLC), which accounts for 81% of cases, and small cell lung cancer (SCLC), which accounts for 14% of cases. NSCLC is further categorized as adenocarcinoma, which is slightly more common in women, followed by squamous cell carcinoma and large cell carcinoma.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"22-29"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in neuroendocrine neoplasms.","authors":"Chrisanthi Zouli,&nbsp;Eleana Zisimopoulou,&nbsp;Alexandra Chrisoulidou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neuroendocrine tumors are a heterogenous group of rare neoplasms with different morphological features, immunophenotype, molecular profile, and clinical presentation. They can derive from any neuroendocrine cell throughout the body, but the majority of NENs is developed in the gastrointestinal tract. They can be divided into two groups, based on hormone secretion, functioning and non-functioning NENs. The first group is characterised from the secretion of specific substances, defining the clinical manifestations. Functional NENs can be divided into carcinoid tumors, with serotonin overproduction, and functional GEP NEN's (mostly located in pancreas) that may secrete insulin, VIP, gastrin, glucagon or somatostatin. Non-functioning NENs, comprise approximately 85% of NEN's. As these tumors lack specific symptoms, they come to clinical attention later, when they have a large size or metastases. Apart from the specific biomarkers that functional NENs are producing, there are some general markers that are produced from all NENs and play a major role in the diagnosis, prognosis and follow up of these patients. These are chromogranin (CgA), neuron-specific enolase (NSE) and 5-hydroxyindolic acetic acid (5-HIAA).</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"44-48"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The progress in multiple myeloma.","authors":"P Hatjiharissi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a neoplastic disease characterized by the proliferation of clonal plasma cells. This disease arises from an initial asymptomatic stage known as monoclonal gammopathy of unknown significance (MGUS). The clinical phenotype that lies between MGUS and MM is commonly known as smoldering multiple myeloma (SMM). In individuals with MGUS and SMM, the risk of progression to MM persists constantly. In MGUS, the progression rate to MM or a related malignancy is around 1% per year, while in SMM, the progression rate to MM is approximately 10% per year. Recently, myeloma was defined as a clonal proliferation of malignant plasma cells that results in end organ damage or myeloma-defining events. MM is a genetically complex disease that exhibits clinical and biological diversity. Currently, the revised International Staging System (R-ISS) is used for prognostication in newly diagnosed patients. For transplant-eligible patients with newly diagnosed MM, the standard of care treatment (SoC) regimen is induction therapy, followed by ASCT and maintenance therapy. In general, the recommended induction therapy is a triplet or quadruplet-agent therapy consisting of a proteasome inhibitor, an immunomodulatory compound, and/or a CD38 antibody in combination with dexamethasone. Myeloma patients who are ineligible for a transplant are typically treated with a triplet combination, which necessitates specialized knowledge of treatment adverse effects. Although the prognosis for patients with MM has significantly improved over time due to advances in treatment, the disease remains incurable and relapses are common. Because various immunotherapeutic agents, new drugs and combinations have become available, selecting the most effective treatment for patients with relapsed/refractory MM needs both art and science.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"30-35"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear Cardio-Oncology.","authors":"Maria Koutelou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nuclear cardio-oncology is a specialized field that combines aspects of nuclear medicine, cardiology, and oncology to diagnose and manage cardiovascular complications in cancer patients. It focuses on the assessment of cardiovascular health and the detection of potential heart-related side effects caused by cancer treatments.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"12-13"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry in MRT: Our recent experience.","authors":"Lydia Angeliki Zoglopitou","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Personalized dosimetry is tending to become the \"gold standard\" in Molecular Radiotherapy (MRT). Setting up carefully all the procedures involved in the workflow is crucial for the final clinical result.</p><p><strong>Aim: </strong>Individualized MRT dosimetry using a recently installed commercial system, comprising of a dual SPECT/CT camera, a treatment planning software (TPS) and a dose calibrator was implemented on patients undergoing ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA therapies. The clinical workflow implemented in our department is presented in detail. Measurement and calculation of the Calibration Factor (CF) to translate the count rate into activity concentration (quantitative data), and system's commissioning, was discussed.</p><p><strong>Materials and methods: </strong>Calibration of the dose calibrator, the SPECT/CT system and the TPS, measured using the clinical acquisition protocol, were analyzed along with potential errors introduced by the procedure and means of future optimization. In addition, image acquisition parameters, image reconstruction and image registration were discussed. Anatomical contouring of the organs at risk (OARs) and functional contouring of the lesions, followed by the dose calculation of the aforementioned structures, with the use of different calculation algorithms, were presented, compared and evaluated.</p><p><strong>Results and discussion: </strong>According to our experience, different fitting of each organ's activity curve, results in differences in the final calculated dose. Use of bi-exponential fitting seems to better approach physical and metabolic decay. Calculated absorbed doses for the OARs were found similar to those expected from literature. Finally, department's future work was discussed, including reproducible patient setup for image acquisition, high dose CT for finer contouring and comparison of the calculated doses with other TPSs.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"15"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer: CT guided BX-EBUS: How and when?","authors":"Miltiadis Krokidis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Histological diagnosis is mandatory for the majority of solid lesions in the lungs in order to characterize the lesions but also to assess the response to treatment. Flexible bronchoscopy has a variable and often poor success rate in sampling pulmonary lesions which are not visible endoscopically. Such focal radiological opacities without endobronchial extension are referred to as peripheral pulmonary lesions and sampling is usually performed under guidance with computed tomography that is a safe and effective technique and became a common procedure representing an essential step for diagnosis and treatment planning. It is usually performed with an 18G or 20G coaxial needle system and several novel guidance and navigation tools may be integrated to clinical practice to offer more accurate lesion targeting. There is however still a percentage of negative sampling a recent study revealed that small lesion size, lower ¹⁸F-FDG uptake or location at the lung bases may lead to inconclusive histology. The diagnostic yield may be increased if PET/CT fusion imaging is used intraprocedurally. CT guided biopsies may also be applied in the same setup with interventions such as ablation of lung lesions offering a \"one-stop\" approach for such patients.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"21"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET/CT: Clinical role in lymphomas.","authors":"Nikolaos Papathanasiou","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT is the imaging modality of choice for the accurate initial staging of most lymphomas. Hodgkin's, Diffuse Large B-cell and follicular lymphomas show avid FDG uptake, while a minority of Non-Hodgkin lymphoma subtypes namely MALT, marginal and small lymphocytic lymphoma demonstrate low or moderate avidity. As a rule of thumb, indolent lymphomas show lower FDG activity than aggressive ones. PET/CT has increased sensitivity in the detection of nodal involvement even in small or normal-sized nodes. It shows higher sensitivity than CT in the detection of extra-nodal disease, most often in the spleen and bone marrow. PET/CT leads to upstaging in up to 25% of Hodgkin lymphomas, paving the way to intensified therapy. It has excellent Negative Predictive Value (NPV&gt;95%) in the detection of bone marrow involvement in Hodgkin's rendering bone marrow biopsy not absolutely necessary: a negative PET rules out bone marrow disease in Hodgkin's patients, yet this does not universally apply in Non-Hodgkin lymphomas. PET/CT is superior to other imaging modalities in the initial stating of aggressive Non-Hodgkin lymphomas detecting disease in previously not suspected or occult sites. &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT is applied in the early therapeutic evaluation of Hodgkin's by means of interim PET performed after 2-3 initial cycles of chemotherapy. Patients with negative interim PET and no hypermetabolic disease identified may continue with the same effective treatment or switch to less aggressive therapy. On the other hand, patients who do not show PET response may be subjected to more intensified treatment to eradicate hypermetabolic active disease. Randomized controlled trials have proven that interim PET/CT shows high NPV for final treatment response and for increased progression free survival in Hodgkin's. The accuracy in reporting and interpretating interim and post-treatment PET/CT has increased by applying specific objective criteria: Deauville 5-score scale. Deauville's uptake scores of 4-5, more intense than liver activity, correspond to active lymphomatous disease. &lt;sup&gt;18&lt;/sup&gt;F-FDG uptake in lesions, equal or lower than mediastinal blood-pool, is interpreted as negative: Deauville scores of 1-2. Role of interim PET is also investigated in Non-Hodgkin Lymphomas, especially nowadays with more effective treatments being applied. PET/CT is highly recommended for post-treatment assessment of lymphomas with excellent NPV and superior diagnostic accuracy compared with CT. After treatment, a significant proportion of patients show residual anatomic lesions on CT f.e. residual mediastinal soft-tissue; yet, in the minority of cases, these lesions correspond to active disease. PET/CT has high diagnostic accuracy in the assessment of residual tissue and may distinguish between PET-negative fibrotic or necrotic tissue and PET-positive, active residual disease. The modality also has high NPV in the evaluation of megatherapy before stem cell tr","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"36-37"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostic in Nuclear Medicine - The paradigm of NET.","authors":"Francesco Giammarile","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Theranostics is an emerging field in medicine that combines diagnostics and therapeutics into a single approach. Overall, theranostics represents a promising paradigm for personalized medicine, as it allows for targeted and precise treatment based on individual patient characteristics. In nuclear medicine, theranostics involves the use of radiopharmaceuticals that have both diagnostic and therapeutic properties. Moreover, theranostics in nuclear medicine offers several advantages over traditional cancer treatments. Unlike radiotherapy, in nuclear medicine the therapy is systemic that targets both primary tumors and metastatic lesions, offering a more comprehensive treatment approach. Additionally, nuclear medicine therapy has been shown to have fewer side effects compared to traditional chemotherapy, making it a more tolerable treatment option for patients. While theranostics in nuclear medicine is still a relatively new field, it has shown promising results in the treatment of neuroendocrine tumors (NETs). One example of a theranostic approach in nuclear medicine is the use of radiolabeled somatostatin analogs for the treatment of NETs. Somatostatin is a hormone that regulates the release of other hormones in the body. It also binds to somatostatin receptors, which are highly expressed in NETs. The first step in theranostics for NETs is the diagnosis and staging of the disease using a radiolabeled somatostatin analog and PET/CT imaging. This allows for the detection of the tumor and assessment of its size and location. Once the tumor has been identified, the same radiolabeled somatostatin analog can be used as a therapeutic agent. The radiopharmaceutical delivers radiation directly to the tumor cells, which destroys them while sparing surrounding healthy tissue. This is known as peptide receptor radionuclide therapy (PRRT). The use of theranostics in NETs also involves the identification of specific somatostatin receptor subtypes that are expressed in the tumor cells. This is important as different somatostatin analogs have varying affinities for different receptor subtypes. By selecting the appropriate radiolabeled somatostatin analog, clinicians can increase the specificity of the therapy, delivering radiation to the tumor cells while minimizing damage to healthy tissue. PRRT has been shown to be effective in treating NETs, particularly those that are resistant to other forms of treatment. It can also be used in combination with other therapies, such as chemotherapy and surgery, to improve outcomes. As research continues, it is likely that theranostics in nuclear medicine will become an increasingly important tool in the fight against cancer, particularly in the context of NETs, offering personalized, targeted treatment options that improve patient outcomes.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"42-43"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid segmentation using perithyroidal halo layer on ^99mTc-pertechnetate thyroid SPECT/CT: An easy and reliable method for accurate quantification of thyroid activity.","authors":"Youngduk Seo,&nbsp;Won Won Lee,&nbsp;Gimun Kang,&nbsp;Min Ho Shong,&nbsp;Kyong Hye Joung,&nbsp;Seong Min Kim,&nbsp;Sungmin Jun","doi":"10.1967/s002449912570","DOIUrl":"10.1967/s002449912570","url":null,"abstract":"<p><strong>Objective: </strong>In previous fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) studies, tumor segmentation using peritumoral halo layer (PHL; SegPHL) was shown to be reliable and accurate segmentation method in various malignant tumors. We found that the halo layer also was observed on the ^99mTc-pertechnetate (^99mTcO₄) thyroid single photon emission computed tomography (SPECT)/CT. In the present study, we attempted to apply thyroid segmentation using the perithyroidal halo layer (PTHL; SegPTHL) on ^99mTcO₄ thyroid SPECT/CT and compared SegPTHL with CT-based thyroid segmentation (SegCT).</p><p><strong>Subjects and methods: </strong>A total of 33 patients (19 females, 14 males; mean age, 46.91±15.7 years old) were enrolled in this study. For SegCT, three-dimensional volume of interest (VOI) of the thyroid was generated via multiple 2-dimensional regions of interest (ROI) along the thyroid margin on transaxial CT images that were manually drawn slice by slice. The PTHL was easily identified by an abrupt increase in layer thickness with minimal or mild distortion of the main thyroid contour, and the thyroid margin for SegPTHL was determined at the innermost portion of PTHL. An automated VOI generation for SegPTHL was performed using the Q. Volumetrix software. The correlation and reliability tests were performed between the quantification parameters of SegPTHL and SegCT.</p><p><strong>Results: </strong>The PTHL threshold adjusted according to maximal SUV of thyroid were similar to the results of previous SegPHLstudies of ¹⁸F-FDG PET/CT. A good correlation was observed between the thyroid volumes of SegCT and SegPTHL (r=0.725; P<0.0001), although the thyroid volume of SegPTHL was slightly larger than that of SegCT (P=0.0017). The % thyroid uptake (TcTU), total lesion activity (TLA), and mean standardized uptake value (SUVmean) of SegPTHL correlated well with those of SegCT (r=0.9877, 0.9883, 0.9875, respectively; P<0.0001). No significant error was observed between the parameters (i.e., TcTU, TLA, and SUVmean) of SegPTHL and SegCT.</p><p><strong>Conclusion: </strong>Thyroid segmentation PTHL may be a useful method for reliable quantification of thyroid uptake, because the SPECT/CT parameters of SegPTHL were strongly correlated with those of SegCT, as well as the process of SegPTHL is easier and faster than that of SegCT.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"84-93"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10045774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}